GKOS - Glaukos Corp

GKOS - Glaukos Corp

https://www.glaukos.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Glaukos Builds Dual Growth Engines Amid Market Headwinds

Zacks Commentary • 1 week, 6 days ago • score: 0.39

GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.

Glaukos ( GKOS ) Q2 Revenue Jumps 30%

Motley Fool • 1 month, 2 weeks ago • score: 0.28

Glaukos ( NYSE:GKOS ) , a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of $124.1 million, beating analyst expectations of $115.5 million by 7.4%.

GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised

Zacks Commentary • 1 month, 2 weeks ago • score: 0.24

Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.

Glaukos ( GKOS ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 2 weeks ago • score: 0.15

Glaukos (GKOS) delivered earnings and revenue surprises of +7.69% and +8.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks

Zacks Commentary • 2 months ago • score: 0.40

GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.

What Makes Glaukos ( GKOS ) a New Buy Stock

Zacks Commentary • 2 months, 4 weeks ago • score: 0.31

Glaukos (GKOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.

52W High

$163.71

52W Low

$77.10

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.77

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

1666.67

EV/EBITDA (<8 favorable)

-57.89

EV/Revenue (<3 favorable)

12.05

P/S (TTM) (<3 favorable)

12.44

P/B (<3 favorable)

7.04

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

3.31%

Institutions (25–75% balanced)

107.34%

Shares Outstanding

57,350,000

Float

55,401,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

432,953,000

Gross Profit (TTM)

330,522,000

EPS (TTM)

-1.61

Profit Margin (>10% good)

-0.21%

Operating Margin (TTM) (higher better)

-0.18%

ROE (TTM) (>15% strong)

-0.13%

EPS YoY (Quarterly) (>10% good)

18.96

Revenue YoY (Quarterly) (>8% good)

0.30

Momentum

Bearish momentum

Value

-1.8140

Previous

-1.0104

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025